In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Purified exosome product and extracellular vesicles: treatment for acute myocarditis, dilated cardiomyopathy and heart failure

Session Rapid Fire 1 - Basic Science

Speaker Katelyn Bruno

Congress : Heart Failure 2019

  • Topic : basic science
  • Sub-topic : Basic Science - Cardiac Biology and Physiology: Microvesicles, Exosomes
  • Session type : Rapid Fire Abstracts
  • FP Number : 13

Authors : K Bruno (Jacksonville,US), DN Diflorio (Jacksonville,US), AR Hill (Jacksonville,US), PG Stalboerger (Rochester,US), LT Cooper Jr (Jacksonville,US), A Behfar (Rochester,US), D Fairweather (Jacksonville,US)

Authors:
K Bruno1 , DN Diflorio1 , AR Hill1 , PG Stalboerger2 , LT Cooper Jr1 , A Behfar2 , D Fairweather1 , 1Mayo Clinic, Cardiovascular Diseases - Jacksonville - United States of America , 2Mayo Clinic - Rochester - United States of America ,

Citation:

Background: Myocarditis is an important cause of heart failure and sudden cardiac death in children and young adults with no targeted treatment to reduce/prevent disease.

Purpose: We wanted to determine whether purified exosome product (PEP) or premenopausal PEP (pmPEP) could improve and/or prevent myocarditis and prevent dilated cardiomyopathy (DCM) using a preclinical mouse model of myocarditis/DCM. We looked at pmPEP because estrogen protects women from myocarditis and heart failure. We also investigated if Adipose Derived Extracellular Vesicles (AEV) was a more effective and efficient treatment product.

Methods: We administered PEP, pmPEP or AEV vs. control ip to male BALB/c mice at day -1, 0 and +1 with virus inoculation on day 0 to induce myocarditis, and harvested mice at day 10 post infection (pi) during the peak of acute myocarditis. Next we treated male BALB/c mice with PEP, pmPEP, AEV or control ip on day 7, 8 and 9 pi (a clinically relevant timepoint) and harvested on day 10 pi during acute myocarditis or day 35 pi during DCM.

Results: We found that the dose and exposure route were successful. pmPEP and AEV, but not PEP, significantly decreased acute myocarditis based on histology (ANOVA p=0.0009) and decreased total immune cells (CD45 p=0.008). Importantly, CR1, the central inhibitor of the complement cascade, was significantly increased by pmPEP (p=0.004). Visual qualitative observations in AEV treated mice indicated improved health in mice receiving regenerative treatment. Body weight was also significantly increased in mice treated with AEV indicating improved health. When assessing clinically relevant dosing timepoint we that found that both PEP and pmPEP treatment given during myocarditis significantly reduced inflammation compared to PBS (ANOVA PEP p=0.006, pmPEP p= 0.005) and decreased fibrosis when assessed at day 35pi

Conclusion: These findings suggest that regenerative medicine treatments; PEP, pmPEP and AEV, could be administered to patients who present with acute onset myocarditis to decrease the severity of disease and potentially prevent heart failure and sudden death.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are